3-(4-甲氧基-1-萘)丙烯酸 | 15971-30-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: 3-(4-甲氧基-1-萘)丙烯酸
• 英文名称: 1-(2-carboxyethenyl)-4-methoxynaphthalene
• 英文别名: 3-(4-methoxynaphthyl)acrylic acid；3t-(4-methoxy-naphthyl-(1))-acrylic acid；3t-(4-Methoxy-naphthyl-(1))-acrylsaeure；3-(4-Methoxy-1-naphthyl)acrylic acid；(E)-3-(4-methoxynaphthalen-1-yl)prop-2-enoic acid
• CAS: 15971-30-9
• 化学式: C₁₄H₁₂O₃
• 分子量: 228.247
• InChiKey: BDWSMCXLZKKQFV-VQHVLOKHSA-N

物化性质

• 熔点：
  225°C
• 沸点：
  185-200 °C(Press: 40 Torr)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  3-(4-甲氧基-1-萘)丙烯酸 在 溴 、 sodium carbonate 作用下， 以 二氯甲烷 、 氯仿 、 水 为溶剂， 生成 1-(2-bromoethenyl)-4-methoxynaphthalene
  参考文献：
  名称：

  Benzophenalenofurans

  摘要：

  这些化合物是苯并菲诺呋喃，具有药理活性，特别是冠状动脉扩张剂活性。

  公开号：

  US03985896A1
• 作为产物：
  描述：

  丙二酸 、 4-甲氧基-1-萘甲醛 在 哌啶 、 吡啶 作用下， 生成 3-(4-甲氧基-1-萘)丙烯酸
  参考文献：
  名称：

  Untersuchungen in der Reihe der Isochinoline. IV. Teil. Synthesen von Benzo-Isochinolonen und Untersuchung der Methoden, Isochinoline aus dem Naphthalinring herzustellen

  摘要：

  DOI：

  10.1002/ardp.19392770805

文献信息

• Therapeutic agents for use in the treatment of parkinson's disease
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0565377A1

  公开（公告）日：1993-10-13

  Disclosed are therapeutic agents for use in the treatment of Parkinson's disease, such agents being xanthine derivatives of the Formula (I) and their pharmaceutical acceptable salts : where R1, R2 and R3 are each H, C1-C6 alkyl or allyl ; and R4 is cycloalkyl of 3 to 8 carbon atoms, a -(CH2)n-R5 group where n is an cycloalkyl of 3 to 8 carbon atoms, a - (CH2)n-R5 group where n is an integer of from 0-4 and R5 is an aryl group of 6 to 10 carbon atoms or a heterocyclic group, such aryl or heterocyclic group optionally being substituted by up to 3 substituent(s) selected from C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halogen, nitro and amino ; or a group, where Y1 and Y2 are each H or CH3 and Z is a substituted or unsubstituted aryl or heterocyclic group as defined under R5.

  本发明揭示了治疗帕金森病的治疗剂，该治疗剂为公式（I）的黄嘌呤衍生物及其药物可接受的盐：其中，R1、R2和R3分别为H、C1-C6烷基或丙烯基；而R4为3至8个碳原子的环烷基，-(CH2)n-R5基团，其中n为3至8个碳原子的环烷基，-(CH2)n-R5基团，其中n为0-4的整数，而R5为6至10个碳原子的芳基基团或杂环基团，所述芳基或杂环基团可选地被选自C1-C6烷基，羟基，C1-C6烷氧基，卤素，硝基和氨基的最多3个取代基所取代；或Y1和Y2分别为H或CH3，而Z为根据R5所定义的取代或未取代的芳基或杂环基团的一个基团。
• ANTIDEPRESSANT
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0628311A1

  公开（公告）日：1994-12-14

  An antidepressant containing an active ingredient comprising a xanthine derivative represented by general formule (I) or a pharmacologically acceptable salt thereof, wherein R¹, R² and R³ may be the same or different from one another and each represents hydrogen, lower alkyl, alkyl or propargyl; R⁴ represents cycloalkyl, -(CH₂)n-R⁵ (wherein R⁵ represents optionally substituted aryl or optionally substituted heterocyclic group, and n represents an integer of 0 to 4) of group (A) wherein Y¹ and Y² may be the same or different from each other and each represents hydrogen, fluorine or methyl, and Z represents optionally substituted aryl, group (B) (wherein R⁶ represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino, and m represents an integer of 1 to 3), or optionally substituted heterocyclic group; and X¹ and X² may be the same or different from each other and each represents O or S.

  一种含有活性成分的抗抑郁剂，其活性成分包含通式(I)所代表的黄嘌呤衍生物或其药理上可接受的盐，其中 R¹、R² 和 R³ 可以相同或彼此不同，且各自代表氢、低级烷基、烷基或丙炔基；R⁴ 代表(A)基团的环烷基、-(CH₂)n-R⁵（其中 R⁵ 代表任选取代的芳基或任选取代的杂环基团，且 n 代表 0 至 4 的整数），其中 Y¹ 和 Y² 可以相同或不同，且各自代表氢、氟或甲基，Z 代表任选取代的芳基、基团 (B)（其中 R⁶ 代表氢、羟基、低级烷基、低级烷氧基、卤素、硝基或氨基，m 代表 1 至 3 的整数）或任选取代的杂环基团；X¹ 和 X² 可以相同或不同，各自代表 O 或 S。
• Method of making an antimicrobial multilayer film
  申请人：Cryovac, LLC

  公开号：US11325357B2

  公开（公告）日：2022-05-10

  The presently disclosed subject matter is generally directed to packaging materials having at least one antimicrobial agent and methods of making thereof. A multilayer film including a sealant layer with a polymeric substrate, a lauroyl arginate moiety, and an ethylene methacrylic acid copolymer is disclosed. Such packaging materials are suitable for use in the packaging of food products to control microbial contamination.

  目前公开的主题一般涉及具有至少一种抗菌剂的包装材料及其制造方法。本发明公开了一种多层薄膜，包括具有聚合物基材、精氨酸月桂酰基和乙烯-甲基丙烯酸共聚物的密封层。这种包装材料适用于食品包装，以控制微生物污染。
• Synthesis and Identification of Small Molecules that Potently Induce Apoptosis in Melanoma Cells through G1 Cell Cycle Arrest
  作者：Robin S. Dothager、Karson S. Putt、Brittany J. Allen、Benjamin J. Leslie、Vitaliy Nesterenko、Paul J. Hergenrother

  DOI：10.1021/ja042913p

  日期：2005.6.1

  Late-stage malignant melanoma is a cancer that is refractory to current chemotherapeutic treatments. The average survival time for patients with such a diagnosis is 6 months. In general, the vast majority of anticancer drugs operate through induction of cell cycle arrest and cell death in either the DNA synthesis (S) or mitosis (M) phase of the cell cycle. Unfortunately, the same mechanisms that melanocytes possess to protect cells from DNA damage often confer resistance to drugs that derive their toxicity from S or M phase arrest. Described herein is the synthesis of a combinatorial library of potential proapoptotic agents and the subsequent identification of a class of small molecules (triphenyl methylamides, TPMAs) that arrest the growth of melanoma cells in the G1 phase of the cell cycle. Several of these TPMAs are quite potent inducers of apoptotic death in melanoma cell lines (IC50 similar to 0.5 mu M), and importantly, some TPMAs are comparatively nontoxic to normal cells isolated from the bone marrow of healthy donors. Furthermore, the TPMAs were found to dramatically reduce the level of active nuclear factor kappa-B (NF kappa B) in the cell; NF kappa B is known to be constitutively active in melanoma, and this activity is critical for the proliferation of melanoma cells and their evasion of apoptosis. Compounds that reduce the level of NF kappa B and arrest cells in the G1 phase of the cell cycle can provide insights into the biology of melanoma and may be effective antimelanoma agents.
• Therapeutic agents for use in the treatment of Parkinson's Disease
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：EP0565377B1

  公开（公告）日：1998-01-07